Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2019 Earnings Conference Call Transcript
Nov 07, 2019 • 08:00 am ET
Ladies and gentlemen, thank you for standing by, and welcome to the Atara Biotherapeutics Q3 2019 Financial Results Call. [Operator Instructions] After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
I'd now like to hand the conference over to your speaker today Dr. John Craighead, Vice President of Investor Relations and Corporate Communications of Atara Biotherapeutics. Please go ahead, sir.
Thank you, operator. Good morning, everyone, and welcome to Atara's third quarter 2019 conference call. On today's call, we plan to discuss our third quarter financial results, as well as recent clinical, operational, and strategic progress.
Earlier this morning, we issued a press release providing an overview of the company's third quarter 2019. This press release as well as an updated investor presentation are available in the Investors & Media section of atarabio.com.
I am joined on today's call by Dr. Pascal Touchon, President and Chief Executive Officer; Utpal Koppikar, Chief Financial Officer; and Dr. AJ Joshi, Chief Medical Officer. We will begin with prepared comments from Pascal, and then open the call for your questions.
We'd like to remind listeners that the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and the company's SEC filings. These statements are made as of today's date, and the company undertakes no obligation to update these statements.
Now, I'd like to turn the call over to Atara's President and Chief Executive Officer, Pascal Touchon. Pascal?
Thank you, John, and thank you everyone for joining us this morning.
Before we begin our discussion on our recent progress, I want to reinforce how proud I am of the advances we've made toward a vision of delivering an off-the-shelf, allogeneic T-cell immunotherapy to every patient in need at anytime. We know that life depend on us achieving this vision, and our team is strongly motivated every day to deliver meaningful results for patients and the company.
During today's call, we'll provide context surrounding our new strategic priorities, recent clinical and operational progress and upcoming milestones.
First, I would like to update you on Atara's strategic objective and priority, following the extensive review of technologies, assets, resources, and organization, that I have conducted during my first months as CEO. Objective, moving forward is to become the leading off-the-shelf, allogeneic T-cell immunotherapy company, transforming the life of patients with cancer, autoimmune and viral diseases.
We are planning to accomplish this objective over the next three years, by executing resolutely on four strategic priorities. First and foremost, file and launch tabelecleucel or tab-cel for patients with relapsed/refractory EBV positive PTLD in the U.S. and Europe, as well as develop tab-cel for other indications. Second, achieve clinical proof-of-concept with ATA188 or allogeneic MS specific EBV T-cell immunotherapy. Third, advance mesothelin programs with autologous ATA2271 and allogeneic ATA3271. And